TRP_1170x120_3-8-19

CURE Pharmaceutical and Canopy Growth to produce CBD oral thin films

Print Friendly, PDF & Email

OXNARD, Calif.CURE Pharmaceutical announced it is collaborating with Canopy Growth Corp. to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm technology for global distribution. This CUREfilm license gives Canopy a dosage form that is ideal for administering cannabinoids.

“This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, chief executive officer of CURE Pharmaceutical. “We will leverage our recent patented developments in cannabis-based drug delivery, to formulate an oral thin film product for optimal efficacy and dosing frequency.”

CURE is registered with the U.S. Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, Calif for pharmaceutical applications. CURE is also pursuing federally compliant industrial hemp-based products in the United States by collaborating with cannabis growers and extractors.


CMP_728x90

INNOV_728x90_8-1-17

Comments are closed.